These data contrast with the high percentage of γH2AX foci/geminin-positive cells we observed in ovarian cancers originating from patient-derived xenografts, in which the low number of RAD51 foci predicted olaparib response [22]. The gene discussed is RAD51; the disease is ovarian cancer.